Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected millions of people worldwide, and pneumonia affects 90% of patients. This raises the possibility of millions of people with altered lung function. Few data exist to date on pulmonary function after SARS-CoV-2 infection, but alteration of diffusion capacity of CO (DLCO) is the most frequently described abnormality. First, we present original data on lung function at 3 months after SARS-CoV-2 infection and discuss the effect of using European Coal and Steel Community (ECSC) or Global Lung Function Initiative (GLI) reference equations to diagnose diffusion capacity. Second, we review existing data on DLCO alteration after SARS-CoV-2 infection and discuss the implication of restrictive disorder in DLCO alteration. Last, we discuss the pathophysiology of DLCO alteration and try to disentangle vascular damage and fibrosis.
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected more than 100 million of people worldwide and more than 60 million have recovered (). Pneumonia affects more than 90% of patients and can range clinically from asymptomatic to acute respiratory distress syndrome. The radiological extent of pneumonia can be classified as absent, mild (<10% of parenchyma involved), moderate (10–24%), wide (25–49%), severe (50–74%), or very severe (>75%), according to European guidelines (). The high number of affected people raises concern about the possibility of having millions of people with altered pulmonary function tests (PFTs). To date, few data exist on the frequency of clinically relevant PFT abnormalities after coronavirus disease 2019 (COVID-19), but alteration of diffusion capacity (DLCO) is the most frequently described feature (; ; ). However, PFT are not accessible worldwide, and a better knowledge of the pathophysiology underlying DLCO alteration could help prioritize patients for PFT access. In this article, we review existing data on PFT results after SARS-CoV-2 infection, discuss the possible pathophysiology of DLCO alteration, and present original data on the importance of using appropriate reference equations for assessing normality of PFT.
Diffusion Capacity Alteration After COVID-19 Is Frequent and Independent of Initial Clinical Severity
The transfer (or diffusion) conductance of the lung for carbon monoxide (DLCO) is measured using the single apnea method, by multiplying two values that can be considered independent, namely (1) the alveolar volume (VA), which is the lung volume where inhaled helium diffuses in gas state following inspiration from residual volume to total lung capacity and (2) the carbon monoxide transfer coefficient (kCO), which is the rate constant for carbon monoxide uptake in the lung. Thus, DLCO can be reduced by reduction in lung volumes (restriction) or reduction in carbon monoxide uptake. Since carbon monoxide uptake depends on the integrity of the alveolar–capillary membrane and the presence of hemoglobin across the alveolar–capillary membrane, any alteration in either alveolar lung regions or the pulmonary vasculature results in reduced DLCO. In addition, although kCO increases with reductions in lung inflation, this relationship is not proportional (); thus, restriction due to reduced chest wall compliance or respiratory muscle weakness may result in reduced DLCO. Since DLCO depends on the integrity of almost all structures of the respiratory system (conducting airways excluded), it is highly sensitive to detect lung disease. Because kCO depends on lung inflation, it is difficult to interpret in restrictive lung disease where low lung volumes may result from reductions in chest wall compliance, inspiratory muscle weakness, or reduced lung compliance.
The Importance of Choosing the Right Predicted Values
We conducted a retrospective study on patients with confirmed SARS-CoV-2 infection (PCR) referred at 3 months after symptom onset for pulmonary PFT. Patients were referred to the PFT laboratory if they had presented with severe COVID-19 (i.e., had required at least 6 L/min oxygen or mechanical ventilation during acute infection) or if they still had respiratory symptoms at 3 months. Comparisons between groups used Mann–Whitney and Kruskal–Wallis (with Dunns’ multiple comparisons tests) tests for continuous variables and chi-2 or Fisher’s exact tests for categorical variables (Prims 8, Graphpad, San Diego, United States). Non-opposition was obtained for all patients, according to French law. The study was approved by the Institutional Review Board of the French Learned Society for Respiratory Medicine—Société de Pneumologie de Langue Française (ref 2020-056).
We included 146 patients [median age, 58 (Q1 = 49; Q3 = 67); median body mass index (BMI), 27.15 kg/m (24.72;30.35), 89 (61%) men]. Complete characteristics of patients are presented in Table 1.
TABLE 1
| All (n = 151) | |
| Age, years | 57(49;67) |
| Male sex | 91 (60) |
| BMI, kg/m2 | 27.29(24.72;30.35) |
| Respiratory comorbidities | |
| Asthma | 10 (7) |
| COPD | 9 (6) |
| Bronchiectasis | 2 (1) |
| Sarcoidosis | 3 (2) |
| Idiopathic pulmonary fibrosis | 1 (0.01) |
| Lymphangioleiomyomatosis | 1 (0.01) |
| Lung transplant | 1 (0.01) |
| Hypertension | 25 (17) |
| Smoking status | |
| Active | 11 (7) |
| Former | 9 (6) |
| Respiratory support | |
| None | 37 (25) |
| Oxygen 0–6 L/min | 61 (40) |
| Oxygen > 6 L/min | 13 (8) |
| High flow nasal canula/CPAP | 14 (9) |
| Invasive ventilation | 26 (17) |
| Initial pneumonia on chest CT | |
| No chest CT | 22 (15) |
| Absent | 3 (2) |
| Mild | 13 (8) |
| Moderate | 37 (25) |
| Wide | 42 (28) |
| Severe/extremely severe | 34 (23) |
| Pulmonary function tests | |
| FEV1 (% pred) | 109(91;119) |
| FVC (% pred) | 109(93;119) |
| FEV1/FVC | 0.72(0.71;0.73) |
| TLC (% pred) | 103(90;115) |
| DLCO (CECA,% pred) | 71(69;72) |
| DLCO (GLI,% pred) | 74(63;84) |
Patients’ characteristics.
Results are presented as median (Q1;Q3) for continuous variables or n (%) for categorical variables. Extent of pneumonia on initial CT was defined as absent, mild (<10%), moderate (10–24%), wide (25–49%), or severe/extremely severe (≥50%) ().
To assess the effect of reference equations on altered diffusion capacity prevalence, we determined percent of predicted value for European Coal and Steel Community (ECSC) 93 () and Global Lung Function Initiative (GLI) () reference equations; altered diffusion capacity was defined as DLCO < LLN. Median (% pred) DLCO were 70 (69;72) for ECSC 93 and 72 (63;84) for GLI, p < 0.0001. Interestingly, when using ECSC 93 reference equations, 71 (49%) patients had altered diffusion capacity (among which light n = 30, moderate n = 36, severe n = 5), while 76 (54%) patients were diagnosed with altered DLCO when using GLI reference equations (light n = 49, moderate n = 29, severe n = 3, p = 0.0231 for disease severity) (see Figure 1).
FIGURE 1
We determined the difference in predicted value between GLI and ECSC 93: DeltaDLCO = DLCO%pred GLI − DLCO%pred ECSC. There was an inverse correlation between age and DeltaDLCO with a Spearman correlation coefficient r = −0.3588 (IC95 −0.4962; −0.039, p < 0.0001). There was a significant difference in DeltaDLCO between men (median difference = 10) and women (median difference = 4, p < 0.0001).
Although more patients were diagnosed as having altered DLCO with GLI, the severity of alteration was milder. compared DLCO (%pred) in 4,903 healthy never-smoking, middle-aged adults from the SCAPIS cohort. They found that the GLI LLN for DLCO was lower than the estimated LLN by lambda–mu–sigma (LMS) method. Individuals with DLCO above the GLI LLN but below the SCAPIS LLN had, to a larger extent, an increased respiratory burden. In chronic respiratory diseases, showed that using GLI reference equations significantly enhances the number of patients who are eligible to clinical studies with a DLCO threshold >30%. showed on a retrospective study on 33,863 DLCO measures that, when using GLI equations, results were reclassified from abnormal to normal more frequently for younger adults and for female adults and that this effect was of different size depending on the DLCO reference equation used (Crapo, Miller, or Roca). As for all lung function measurements (), it is essential that appropriate reference values are used and that the criteria used to define altered DLCO associate with clinical outcomes. This point is not trivial since authors do not always report the reference equations used for diagnosing abnormal DLCO (), and some authors use a fixed cutoff value of 80% (), whereas others use the 5th centile or LLN (). In addition, in our cohort, 49% of the subjects were Caucasian; thus, the prevalence obtained in other countries might not be the same.
Of note, the Global Lung Function Initiative very recently published an erratum on the reference equation for DLCO that affected the predicted values for female adult and for the calculation of z-scores in female adults (). These modified equations are not implemented in most PFT software to date and thus cannot be used by clinicians, but the differences are minimal.
Current Knowledge on Diffusion Capacity Alteration After COVID-19
Limited data exist on pulmonary function in SARS-CoV-2 survivors. In the study by , at hospital discharge, anomalies were noted in DLCO (% pred) in 51 cases (47.2%) of the 110 patients. There was a significant difference in impaired diffusing capacity among the different groups of severity, which accounted for 30.4% in mild illness, 42.4% in pneumonia, and 84.2% in severe pneumonia, respectively (p < 0.05). In the study by , at 1 month after symptom onset, median DLCO was 80 (Q1 70; Q3 92), but 30% (15/50) of the patients had altered diffusion capacity (defined as DLCO < LLN). There was no difference in DLCO (% pred values) between groups of CT extent but a significant difference in the proportion of abnormal values (p = 0.0277). Lower DLCO (% predicted value) was significantly associated with older age (>50 years) (p = 0.0351); there was no significant difference between groups of clinical severity (i.e., oxygen requirement). In a study by , among 55 patients evaluated at 3 months after symptom onset, 71% had abnormal chest CT, but only 16% of patients had DLCO < 80% pred. Of note, in this study, only four patients had severe pneumonia (i.e., requiring oxygen), and four patients were included but had no radiological pneumonia. The higher prevalence of diffusion capacity alteration in our data is likely explained by the inclusion of 17% of patients who had required invasive ventilation. In the prospective study by , 58% of the 60 included patients had abnormal DLCO at 3 months, and 88% of them had abnormal chest CT.
Data are absent for patients with chronic respiratory diseases. reported that COPD increases all-cause mortality in patients with COVID-19, but no functional data during follow-up were available.
Altogether, these studies highlight the fact that more than half of the patients have altered DLCO after SARS-CoV-2 infection and that lower DLCO is related to older age and severe-to-extremely severe radiological pneumonia. Pre-SARS-CoV-2 pulmonary function was not available in published series, but most patients included were devoid of chronic respiratory diseases. In a recent meta-analysis on 378 survivors of MERS and SARS-CoV, report that DLCO < 80% pred has a pooled estimate of 24.35 (95% confidence interval, 11.05–45.46) at 6 months. Despite a much smaller number of affected patients worldwide and the inclusion of only severe cases in the meta-analysis, this is markedly lower than in SARS-CoV-2 survivors.
Alteration of DLCO: Vascular Disease, Fibrosis, or Both?
Association Between Altered DLCO and Restriction
In studies assessing pulmonary function at 1 and 3 months (; ; ; ), altered DLCO was the most common abnormality and was often accompanied by restrictive disorder. Restriction can result from reduction in chest wall compliance, reduction in lung compliance, inspiratory muscle weakness, or a combination thereof. Interestingly, any of these pathophysiological alterations may be present in survivors of severe COVID-19 due to COVID-specific extensive lung damage or myositis or complications of prolonged intensive care such as diaphragm dysfunction associated with critical illness myopathy (). In the study by , 25% of patients had TLC < 80%, but the authors do not use LLN to diagnose restriction and do not report specifically patients with altered DLCO and TLC; nonetheless, mean kCO (DLCO/VA) was normal (92% pred value), and TLC and kCO were significantly lower in patients with severe pneumonia. In the study by , altered DLCO alone at 3 months was the most frequent pathological finding (16.36% of patients), but restriction and diffusion alteration were present in only 5.45% of patients. There was a significant correlation with initial D-dimer level, which suggests that vascular thrombosis and/or embolism may contribute to DLCO reduction (). In the data we present here, at 3 months, there was a significant difference in TLC (p < 0.0001) and DLCOGLI (p < 0.0001) but not kCO for patients with residual ground glass opacities compared with normal CT at 3 months. There was a significant difference in TLC between patients with and without obesity (p = 0.0167) but not in DLCOGLI. Radiological emphysema was present in a minority of patients and is unlikely to account for a significant proportion of altered DLCO. This result suggests that alveolar lesions are a key determinant of reduced lung function. Thus, it is unclear if altered DLCO up to 3 months after COVID-19 pneumonia reflects persistent alteration of the alveolar–capillary membrane, reduced lung volumes, or other mechanisms in COVID-19 survivors.
Autopsy Series and Case Reports
In the radiological case series by , the most frequent feature during acute phase was ground glass opacities (GGO), either isolated GGO (86.1%) or mixed GGO and consolidation (64.4%). This was followed by vascular enlargement in the lesion (71.3%) and traction bronchiectasis (52.5%). At discharge, show that most patients present with consolidation of lesions, with fibrotic lesions remaining only in 12% of cases. Critically ill patients had more often consolidation and bilateral lung involvement (). Unfortunately, most case series reporting radiological fibrosis after COVID-19 included a small number of patients, most who had required mechanical ventilation (either invasive or non-invasive), which in itself can cause lung injury (; ).
report the case of a 38-year-old man who presented with extensive pulmonary honeycombing fibrosis in territories where GGO had been initially present, 10 days after symptom onset, and without invasive ventilation. Similarly, report the case of a 80 years old woman who had normal chest CT prior to infection and died of diffuse lung fibrosis.
Several histopathological series have been published (; ). Although all reported a high prevalence of microthrombi and vascular lesions in deceased patients, the presence of alveolar damage was inconsistent. Polak et al. reviewed 129 cases of published lung samples (either full/partial autopsy or lung resection) and identified three main histological patterns: epithelial (n = 110, 85%), with reactive epithelial changes and diffuse alveolar damage (DAD); vascular (n = 76, 59%) with microvascular damage, (micro)thrombi, and acute fibrinous and organizing pneumonia; and fibrotic (n = 28, 22%) with interstitial fibrosis. The epithelial and vascular patterns were present in all stages, whereas the fibrotic pattern started at 3 weeks of evolution. Patients could present with more than one pattern, either simultaneously or consecutively. Unfortunately, chest CT results were not reported; the presence of fibrosis was not associated with mechanical ventilation.
These differences could be explained by different inclusion criteria (deceased patients vs. lung sample), number of cases in the series, and difference in time from diagnosis to lung specimen. Indeed, most patients died after several days or weeks under ventilator support, which can lead to lung injury despite protective measures ().
Vasculopathy, Fibrosis, or Both?
The key receptor to SARS-CoV-2 entry, angiotensin−converting enzyme (ACE)-2, is expressed on pneumocytes and macrophages, as well as on the surface of arterial endothelial and smooth muscle cells of the lungs (). Endothelial dysfunction induced by SARS-CoV-2 creates a favorable environment for thrombosis (), which in turn can favor inflammation, representing the immunothrombosis model (). ACE-2 has been shown to be activated in acute lung injury and linked to acute respiratory distress syndrome (ARDS) severity (; ). Using a combined in vitro and in silico approach, showed that SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis, such as TMPRSS2, ADAM metallopeptidase domain 17 (ADAM17), tissue inhibitor of metalloproteinase 3 (TIMP3), angiotensinogen, transforming growth factor beta 1 (TGFB1), connective tissue growth factor (CTGF), vascular endothelial growth factor A (VEGF A), and fibronectin.
Thus, is it possible to explain alteration of DLCO by both fibrosis and vascular disease?
In infiltrative lung diseases (ILDs), recently reviewed the evidence of vascular involvement in fibrosis progression. In systemic sclerosis and idiopathic pulmonary fibrosis (IPF), there is an increase in vascular permeability even during early stages of the disease. There is also evidence for a vascular remodeling and a key role for the hematopoietic-vascular niche in fibrosis promotion ().
As exerted by , endothelial-to-mesenchymal transition (EndMT) can occur when endothelial cells respond to injury and transform themselves in a more aggressive mesenchymal state. The authors point out that histopathological findings in fatal COVID-19 cases reveal important vascular changes that are compatible with EndMT and that this is consistent with the different receptors that facilitate SARS-CoV-2 entry in endothelial cells. The disruption of endothelial cells induced by EndMT facilitates cell migration and can trigger fibrosis.
Neutrophils extracellular traps (NETs) are DNA fibers decorated with proteins normally confined to granules, including antimicrobial molecules. They are implicated in lung damage by promoting differentiation and function of fibroblasts (in vitro) (), thrombosis, and can be formed in response to numerous infectious and non-infectious stimuli (). The presence of NET has been confirmed in the lungs of patients with severe COVID-19, infiltrating airways, interstitium, and vascular compartment (). This ubiquitous presence could result in vascular damage and fibrosis altogether, but all four patients had been under mechanical ventilation and died of respiratory failure, and these findings might not be generalized to all COVID-19 patients. found NETs in bronchoalveolar lavage and blood of patients with ARDS but no significant relationship between bronchoalveolar lavage neutrophil extracellular trap concentrations and ventilator-free days.
Conclusion and Perspectives
Alteration of diffusion capacity of the lung is frequent after SARS-CoV-2 infection, although its prevalence and severity depend on the reference equation used. The use of GLI reference equations should be strongly encouraged. It is still unclear if this alteration results from vascular disease (including thrombopathy), fibrotic sequelae, respiratory muscle weakness, or a combination of these factors.
This high prevalence of altered DLCO will induce a high number of patients to follow after infection has resolved and put a pressure on pulmonologists. Giving a wide access to PFT will be crucial (; ; ), but better knowledge on the natural history of COVID-19 could help selecting the patients who may benefit from close and repeated follow-up of DLCO. Different countries might choose different follow-up algorithms, depending not only on their capacity to give access to full PFT (including FRC and DLCO) or spirometry only, but also on the ongoing epidemics that will affect access to PFT and PFT procedures (; ; ). To prevent overwhelming of PFT laboratories, chest CT and/or X-ray have been proposed as screening tools (), but X-ray might not have a high sensitivity to detect sequelae. In addition, these algorithms often rely on persistent symptoms to decide further investigations, and it has been established that dyspnea is present in at least 50% of patients at 3 months, including those with mild initial symptoms (; ). Tools assessing functional status and quality of life are of great importance when evaluating the cost of COVID-19 on patients’ life (). A common frame of surveillance and outcome measures is needed to have access to comparable data worldwide (). The effect of COVID-19 on patients with chronic respiratory diseases needs to be assessed in multicentric cohorts. Finally, the effect of different treatments, particularly steroids, needs to be assessed.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, in respect of the GDPR.
Ethics statement
The studies involving human participants were reviewed and approved by the Institutional Review Board of the French learned society for respiratory medicine – Société de Pneumologie de Langue Française. The patients/participants provided their non opposition to participate in this study.
Author contributions
JF-M: acquisition of data, manuscript writing, and statistics. CB, HB, LM, DP, and MF: acquisition of data, manuscript correction, and final approval. LP and M-Pd’O: manuscript writing and final approval. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AhmedH.PatelK.GreenwoodD. C.HalpinS.LewthwaiteP.SalawuA.et al (2020). Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis.J. Rehabil. Med.52:jrm00063. 10.2340/16501977-2694
2
AndrejakC.BlancF. X.CostesF.CrestaniB.DebieuvreD.PerezT.et al (2020). [Guide for follow-up of patients with SARS-CoV-2 pneumonia. management proposals developed by the French-language Respiratory Medicine Society. Version of 10 may 2020].Rev. Mal. Respir.37505–510. 10.1016/j.rmr.2020.05.001
3
BendibI.de ChaisemartinL.GrangerV.SchlemmerF.MaitreB.HüeS.et al (2019). Neutrophil extracellular traps are elevated in patients with pneumonia-related acute respiratory distress syndrome.Anesthesiology130581–591. 10.1097/ALN.0000000000002619
4
BhattS. P.BalteP. P.SchwartzJ. E.CassanoP. A.CouperD.JacobsD. R.et al (2019). Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality.JAMA3212438–2447. 10.1001/jama.2019.7233
5
BoeltzS.AminiP.AndersH. J.AndradeF.BilyyR.ChatfieldS.et al (2019). To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps.Cell Death Differ.26395–408. 10.1038/s41418-018-0261-x
6
BrazzaleD. J.SeccombeL. M.WelshL.LanteriC. J.FarahC. S.RuehlandW. R. (2020). Effects of adopting the global lung function initiative 2017 reference equations on the interpretation of carbon monoxide transfer factor.Eur. Respir. J.55:1901905. 10.1183/13993003.01905-2019
7
CaoZ.LisR.GinsbergM.ChavezD.ShidoK.RabbanyS. Y.et al (2016). Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis.Nat. Med.22154–162. 10.1038/nm.4035
8
ChrysanthopoulouA.MitroulisI.ApostolidouE.ArelakiS.MikroulisD.KonstantinidisT.et al (2014). Neutrophil extracellular traps promote differentiation and function of fibroblasts: NETs induce fibrosis via differentiation of fibroblasts.J. Pathol.233294–307. 10.1002/path.4359
9
CombetM.PavotA.SavaleL.HumbertM.MonnetX. (2020). Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19.Eur. Respir. J.56:2001808. 10.1183/13993003.01808-2020
10
EapenM. S.LuW.GaikwadA. V.BhattaraiP.ChiaC.HardikarA.et al (2020). Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?Eur. Respir. J.56:2003167. 10.1183/13993003.03167-2020
11
Ers Group 9.1 and Ers Group 4.1 (2020). Recommendation from ERS Group 9.1 (Respiratory Function Technologists/Scientists)Lung Function Testing During COVID-19 Pandemic and Beyond. Available Online at: https://ers.app.box.com/s/zs1uu88wy51monr0ewd990itoz4tsn2h(accessed May 6, 2020).
12
EvansP. C.RaingerG. E.MasonJ. C.GuzikT. J.OstoE.StamatakiZ.et al (2020). Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science.Cardiovasc. Res.1162177–2184. 10.1093/cvr/cvaa230
13
FangY.ZhouJ.DingX.LingG.YuS. (2020). Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: preliminary experience.Am. J. Emerg. Med.382134–2138. 10.1016/j.ajem.2020.05.120
14
Frija-MassonJ.DebrayM. P.GilbertM.LescureF. X.TravertF.BorieR.et al (2020). Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection.Eur. Respir. J.56:2001754. 10.1183/13993003.01754-2020
15
GaertnerF.MassbergS. (2016). Blood coagulation in immunothrombosis—At the frontline of intravascular immunity.Semin. Immunol.28561–569. 10.1016/j.smim.2016.10.010
16
GarriguesE.JanvierP.KherabiY.Le BotA.HamonA.GouzeH.et al (2020). Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19.J. Infect.81e4–e6. 10.1016/j.jinf.2020.08.029
17
GeorgeP. M.BarrattS. L.CondliffeR.DesaiS. R.DevarajA.ForrestI.et al (2020). Respiratory follow-up of patients with COVID-19 pneumonia.Thorax751009–1016. 10.1136/thoraxjnl-2020-215314
18
GoërtzY. M. J.Van HerckM.DelbressineJ. M.VaesA. W.MeysR.MachadoF. V. C.et al (2020). Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?ERJ Open Res.600542–2020. 10.1183/23120541.00542-2020
19
HammingI.TimensW.BulthuisM.LelyA.NavisG.van GoorH. (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. a first step in understanding SARS pathogenesis.J. Pathol.203631–637. 10.1002/path.1570
20
HuW.DongM.XiongM.ZhaoD.ZhaoY.WangM.et al (2020). Clinical courses and outcomes of patients with chronic obstructive pulmonary disease during the COVID-19 epidemic in Hubei, China.Int. J. Chron. Obstruct. Pulmon. Dis.152237–2248. 10.2147/COPD.S265004
21
HuangW.WuQ.ChenZ.XiongZ.WangK.TianJ.et al (2020). The potential indicators for pulmonary fibrosis in survivors of severe COVID-19.J. Infect.10.1016/j.jinf.2020.09.027 Epub ahead of print.
22
JerngJ. S.YuC. J.WangH. C.ChenK. Y.ChengS. L.YangP. C. (2006). Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome.Crit. Care Med.341001–1006. 10.1097/01.CCM.0000206107.92476.39
23
JohnsonD. C. (2000). Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume.Respir. Med.9428–37. 10.1053/rmed.1999.0740
24
Jonhs Hopkins University of Medicine (2018). New Cases of Covid-19 in World Countries. Available online at: https://coronavirus.jhu.edu/data/new-cases(accessed February 21, 2018).
25
KlokF. A.BoonG. J. A. M.BarcoS.EndresM.GeelhoedJ. J. M.KnaussS.et al (2020). The post-COVID-19 functional status scale: a tool to measure functional status over time after COVID-19.Eur. Respir. J.56:2001494. 10.1183/13993003.01494-2020
26
MagroC.MulveyJ. J.BerlinD.NuovoG.SalvatoreS.HarpJ.et al (2020). Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases.Transl. Res.2201–13. 10.1016/j.trsl.2020.04.007
27
MalinovschiA.ZhouX.BakeB.BergströmG.BlombergA.BrismanJ.et al (2020). Assessment of global lung function initiative (GLI) reference equations for diffusing capacity in relation to respiratory burden in the Swedish CArdioPulmonary bioImage Study (SCAPIS).Eur. Respir. J.56:1901995. 10.1183/13993003.01995-2019
28
MenterT.HaslbauerJ. D.NienholdR.SavicS.HopferH.DeigendeschN.et al (2020). Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.Histopathology77198–209. 10.1111/his.14134
29
MoX.JianW.SuZ.ChenM.PengH.PengP.et al (2020). Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.Eur. Respir. J.55:2001217. 10.1183/13993003.01217-2020
30
OrfanosS. E.ArmaganidisA.GlynosC.PsevdiE.KaltsasP.SarafidouP.et al (2000). Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.Circulation1022011–2018. 10.1161/01.CIR.102.16.2011
31
PatelK.StraudiS.Yee SienN.FayedN.MelvinJ. L.SivanM. (2020). Applying the WHO ICF framework to the outcome measures used in the evaluation of long-term clinical outcomes in coronavirus outbreaks.Int. J. Environ. Res. Public Health17:6476. 10.3390/ijerph17186476
32
PellegrinoR. (2005). Interpretative strategies for lung function tests.Eur. Respir. J.26948–968. 10.1183/09031936.05.00035205
33
PetrofB. J. (2018). Diaphragm weakness in the critically Ill: basic mechanisms reveal therapeutic opportunities.Chest1541395–1403. 10.1016/j.chest.2018.08.1028
34
ProbstC. K.MontesiS. B.MedoffB. D.SheaB. S.KnipeR. S. (2020). Vascular permeability in the fibrotic lung.Eur. Respir. J.56:1900100. 10.1183/13993003.00100-2019
35
QianS. Z.HongW. D.LingjieM.ChenfengL.ZhendongF.PanJ. Y. (2020). Clinical characteristics and outcomes of severe and critical patients with 2019 novel coronavirus disease (COVID-19) in Wenzhou: a retrospective study.Front. Med.7:552002. 10.3389/fmed.2020.552002
36
RadermeckerC.DetrembleurN.GuiotJ.CavalierE.HenketM.d’EmalC.et al (2020). Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19.J. Exp. Med.217:e20201012. 10.1084/jem.20201012
37
RaghuG.WilsonK. C. (2020). COVID-19 interstitial pneumonia: monitoring the clinical course in survivors.Lancet Respir. Med.8839–842. 10.1016/S2213-2600(20)30349-0
38
RevelM. P.ParkarA. P.ProschH.SilvaM.SverzellatiN.GleesonF.et al (2020). COVID-19 patients and the radiology department – advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI).Eur. Radiol.304903–4909. 10.1007/s00330-020-06865-y
39
Rovere QueriniP.De LorenzoR.ConteC.BrioniE.LanzaniC.YacoubM. R.et al (2020). Post-COVID-19 follow-up clinic: depicting chronicity of a new disease.Acta Biomed.9122–28. 10.23750/abm.v91i9-S.10146
40
SchwensenH. F.BorreschmidtL. K.StorgaardM.RedstedS.ChristensenS.MadsenL. B. (2020). Fatal pulmonary fibrosis: a post-COVID-19 autopsy case.J. Clin. Pathol.10.1136/jclinpath-2020-206879 Epub ahead of print.
41
ShahA. S.WongA. W.HagueC. J.MurphyD. T.JohnstonJ. C.RyersonC. J.et al (2020). A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations.Thorax10.1136/thoraxjnl-2020-216308 Epub ahead of print.
42
SlutskyA. S.RanieriV. M. (2013). Ventilator-Induced Lung Injury.N. Engl. J. Med.3692126–2136. 10.1056/NEJMra1208707
43
StanojevicS.BrianL. G.CooperB. G.BruceR. T.KimW. C.RichardW. F.et al (2020). Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians.Eur. Respir. J.56:1750010. 10.1183/13993003.50010-2017
44
StanojevicS.GrahamB. L.CooperB. G.ThompsonB. R.CarterK. W.FrancisR. W.et al (2017). Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians.Eur. Respir. J.50:1700010. 10.1183/13993003.00010-2017
45
WangC.ShiB.WeiC.DingH.GuJ.DongJ. (2020). Initial CT features and dynamic evolution of early-stage patients with COVID-19.Radiol. Infect. Dis.7195–203. 10.1016/j.jrid.2020.08.002
46
WapenaarM.MiedemaJ. R.LammeringC. J.MertensF. W.WijsenbeekM. S. (2019). The impact of the new global lung function initiative TLCO reference values on trial inclusion for patients with idiopathic pulmonary fibrosis.Eur. Respir. J.53:1801895. 10.1183/13993003.01895-2018
47
WilsonK. C.KaminskyD. A.MichaudG.SharmaS.NiciL.FolzR. J.et al (2020). Restoring pulmonary and sleep services as the COVID-19 pandemic lessens: from an association of pulmonary, critical care, and sleep division directors and american thoracic society-coordinated task force.Ann. Am. Thorac. Soc.171343–1351. 10.1513/AnnalsATS.202005-514ST
48
XuJ.XuX.JiangL.DuaK.HansbroP. M.LiuG. (2020). SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis.Respir. Res.21:182. 10.1186/s12931-020-01445-6
49
ZhaoW.ZhongZ.XieX.YuQ.LiuJ. (2020b). Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study.AJR Am. J. Roentgenol.2141072–1077. 10.2214/AJR.20.22976
50
ZhaoY.ShangY.SongW.LiQ.XieH.XuQ.et al (2020a). Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery.EClinicalMedicine25:100463. 10.1016/j.eclinm.2020.100463
Summary
Keywords
SARS-CoV-2, DLCO, pneumonia, pulmonary function test, COVID-19
Citation
Frija-Masson J, Bancal C, Plantier L, Benzaquen H, Mangin L, Penaud D, Arnoult F, Flamant M and d’Ortho M-P (2021) Alteration of Diffusion Capacity After SARS-CoV-2 Infection: A Pathophysiological Approach. Front. Physiol. 12:624062. doi: 10.3389/fphys.2021.624062
Received
30 October 2020
Accepted
27 January 2021
Published
25 March 2021
Volume
12 - 2021
Edited by
Ravi Nistala, University of Missouri, United States
Reviewed by
Jordan A. Guenette, University of British Columbia, Canada; Hariharan Regunath, University of Missouri, United States
Updates
Copyright
© 2021 Frija-Masson, Bancal, Plantier, Benzaquen, Mangin, Penaud, Arnoult, Flamant and d’Ortho.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Justine Frija-Masson, justine.frija@aphp.fr; orcid.org/0000-0001-5575-3913
This article was submitted to Respiratory Physiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.